Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.45 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31278567 | 0.86 | MAP3K14 (0.35) | KDM1AKDM1BKCNH2MAP3K14DPP4 | |
| Hydrochloric Acid SCHEMBL1162946 | 0.84 | MAP3K14 (0.34) | MAP3K14DPP4ADRA2A | |
| SCHEMBL20449226 | 0.80 | MAP3K14 (0.49) | KDM1AKDM1BKCNH2MAP3K14PKM | |
| SCHEMBL20449228 | 0.80 | MAP3K14 (0.49) | KDM1AKDM1BKCNH2MAP3K14PKM | |
| SCHEMBL1239165 | 0.72 | ADRA2A (0.50) | KDM1AKDM1BMAP3K14ADRA2A | |
| SCHEMBL12501511 | 0.72 | ADRA2A (0.50) | KDM1AKDM1BMAP3K14ADRA2A | |
| SCHEMBL1239304 | 0.72 | KDM1A (0.41) | KDM1AKDM1BADRA2A | |
| SCHEMBL1163088 | 0.72 | ADRA2A (0.50) | KDM1AKDM1BMAP3K14ADRA2A | |
| SCHEMBL4142656 | 0.72 | ADRA2A (0.50) | KDM1AKDM1BDPP4ADRA2A | |
| SCHEMBL1265663 | 0.72 | KDM1A (0.41) | KDM1AKDM1BADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| EP-3356360-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180291014-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | KDM1A 2269/4885KDM1B 1545/4885KCNH2 765/4885 |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | KDM1A 2269/4885KDM1B 1545/4885KCNH2 765/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | KDM1A 2269/4885KDM1B 1545/4885KCNH2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.